News | June 08, 2022
Halozyme announces commercial launch of testosterone undecanoate 'TLANDO'
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
The drug will be manufactured at the group’s topical facility at Ahmedabad
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Subscribe To Our Newsletter & Stay Updated
